BACKGROUND: Male breast cancer (MBC) is a rare disease whose etiology appears to be largely associated with genetic factors. BRCA1 and BRCA2 mutations account for about 10% of all MBC cases. Thus, a fraction of MBC cases are expected to be due to genetic factors not yet identified. To further explain the genetic susceptibility for MBC, whole-exome sequencing (WES) and targeted gene sequencing were applied to high-risk, BRCA1/2 mutation-negative MBC cases. METHODS: Germ-line DNA of 1 male and 2 female BRCA1/2 mutation-negative breast cancer (BC) cases from a pedigree showing a first-degree family history of MBC was analyzed with WES. Targeted gene sequencing for the validation of WES results was performed for 48 high-risk, BRCA1/2 mutation-negative MBC cases from an Italian multicenter study of MBC. A case-control series of 433 BRCA1/2 mutation-negative MBC and female breast cancer (FBC) cases and 849 male and female controls was included in the study. RESULTS: WES in the family identified the partner and localizer of BRCA2 (PALB2) c.419delA truncating mutation carried by the proband, her father, and her paternal uncle (all affected with BC) and the N-acetyltransferase 1 (NAT1) c.97C>T nonsense mutation carried by the proband's maternal aunt. Targeted PALB2 sequencing detected the c.1984A>T nonsense mutation in 1 of the 48 BRCA1/2 mutation-negative MBC cases. NAT1 c.97C>T was not found in the case-control series. CONCLUSIONS: These results add strength to the evidence showing that PALB2 is involved in BC risk for both sexes and indicate that consideration should be given to clinical testing of PALB2 for BRCA1/2 mutation-negative families with multiple MBC and FBC cases. Cancer 2017;123:210-8. V C 2016 American Cancer Society.
INTRODUCTION
Male breast cancer (MBC) is a rare disease: it accounts for less than 1% of all breast cancers (BCs) and less than 1% of all cancers in men. 1 Approximately 20% of men with BC have a first-degree family history (FH) of BC, and approximately 20% develop a second nonbreast tumor. 2 Overall, these data indicate that genetic factors are associated with the risk of developing MBC.
Inherited mutations in the high-penetrance BRCA2 gene and, to a lesser extent, in the BRCA1 gene predispose men to BC and account for approximately 10% of all MBC cases. In high-risk BC families, BRCA2 mutations are estimated to be responsible for 60% to 76% of MBC cases, whereas BRCA1 mutations account for 10% to 16% of MBC cases. 3, 4 Thus, a fraction of high-risk familial MBC cases remain to be assigned to specific genetic factors.
Germ-line mutations in moderate-penetrance BC susceptibility genes such as checkpoint kinase 2 (CHEK2) and partner and localizer of BRCA2 (PALB2) have also been reported in MBC cases. 4 However, the contribution of these genes to MBC still remains to be precisely assessed. Overall, data on the role of moderate-penetrance genes in MBC susceptibility are sparse and inconclusive, probably because of the low mutation frequency in the general population and the rarity of the disease. [5] [6] [7] [8] Whole-exome sequencing (WES) is a highthroughput technology that allows the sequencing of the 1% to 2% protein-coding subset of the human genome. Recently, it has emerged as a powerful tool for exploring the extent to which rare mutations may explain the heritability of complex diseases, including several types of cancer. 9, 10 Rare mutations involved in BC susceptibility have been found in genes newly identified by WES, such as FANCM and RECQL. 11, 12 To our knowledge, no study has performed WES for MBC cases.
To investigate the genetic component of BRCA1/2 mutation-negative MBC and to identify germ-line mutations that could further explain BC susceptibility, we performed WES in a high-risk, BRCA1/2 mutation-negative BC pedigree with a first-degree FH of MBC. We complemented this with targeted gene sequencing in a large series of high-risk, BRCA1/2 mutation-negative MBC cases.
MATERIALS AND METHODS

Patients
Pedigree selected for WES
A high-risk, BRCA1/2 mutation-negative MBC pedigree was selected for WES analysis from an Italian multicenter study of MBC. [13] [14] [15] The selected family had first-degree relatives affected by BC on both the maternal and paternal sides of the proband, a woman with BC. Specifically, 2 first-degree relatives affected with MBC were on the paternal side, whereas 3 female breast cancer (FBC) cases were on the maternal side. In addition, 4 cancer cases other than BC, including 1 with glioma, 1 with stomach cancer, and 2 with lung cancer, were present in the pedigree. Notably, 1 MBC case was also affected by melanoma (Fig.  1A) . Three BC cases-the proband, 1 MBC case (the paternal uncle), and 1 FBC case (the maternal aunt)-all tested negative for BRCA1/2 mutations, were available for the study, and were examined with WES.
Cases selected for validation
A subset of 48 high-risk, BRCA1/2 mutation-negative MBC cases from the Italian multicenter study of MBC was selected as a validation series [13] [14] [15] on the basis of the following criteria: first-degree breast/ovarian cancer (BC/ OC) FH, MBC onset at 60 years, and bilateral MBC. Notably, 44 cases (91.7%), including 3 patients with a first-degree FH of MBC, had a first-degree FH of BC/ OC, and 28 (58.3%) had a first-degree FH of cancer or cancers at sites other than the breasts and ovaries (mostly prostate and colon cancer). Overall, 24 cases (50%) presented with a first-degree FH of both BC/OC and cancer at other sites. One case presented with contralateral BC, and 7 (14.6%) had a personal history of cancer or cancers at sites other than the breasts. The age at first BC diagnosis ranged from 38 to 83 years; the mean age was 60.4 years.
A case-control series of 331 BRCA1/2 mutationnegative MBC cases unselected for FH, including the 48 high-risk MBC cases, [13] [14] [15] and 631 healthy male controls was used for validation of the results. An additional series of 102 BRCA1/2 mutation-negative FBC patients 16 and 218 healthy female controls was also included as a validation series. Male and female control samples were obtained from individuals enrolled under research or clinical protocols and from blood donors. For each study participant, blood or DNA samples, together with clinicopathologic features for cases, were collected. DNA from blood samples was extracted and quantified as previously described. 13 For some cases, formalin-fixed, paraffin-embedded (FFPE) tumor sections were available. Tumor DNA was extracted from microdissected FFPE sections to ensure at least 60% to 70% of tumor cells with the AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Del) according to the manufacturer's instructions.
The study was approved by the local ethics committee (Sapienza University of Rome, Protocol 264/12).
WES
Genomic DNA was extracted from whole blood samples with the QIAamp DNA Mini Kit according to the manufacturer's instructions (Qiagen). DNA quantity and quality were measured with both fluorometric quantitation by Qubit (Invitrogen, Carlsbad, Calif) and spectrophotometric quantitation by NanoDrop (Thermo Scientific, Waltham, Mass). A total of 10 mg of DNA for each sample was used to prepare in vitro DNA libraries with the TruSeq DNA sample preparation kit and the TruSeq exome enrichment kit (Illumina, San Diego, Calif). Libraries were sequenced on the Illumina HiSeq instrument with a 100-bp paired-end protocol (2 3 100 bp).
Data Analysis
The adopted next-generation sequencing data analysis was close to the one described by D'Antonio et al. 17 In particular, the quality check of the sequenced reads was performed with the NGS QC toolkit (version 2.3.3). 18 This tool discarded low-quality reads after a quality check and removed primer/adaptor sequences. After a qualitycontrol step, the filtered short reads were mapped to the reference genome (hg19) with BWA (version 0.7.10). 19 This is a fast and memory-efficient read aligner based on a data-compression algorithm (the Burrows-Wheeler transform). SAMtools was used in the variant calling preprocessing phase to order the reads by chromosomal coordinates and merge the paired and unpaired BAM files of the same sample. 20 The realigner tool of the Genome Analysis Tool Kit (GATK; version 2.8-1) was used to perform a local realignment around insertion/deletions (indels) to correct misalignments (due to indels); consensus indels were obtained, and false-positives were reduced. 21, 22 The GATK recalibration tool was adopted to recalibrate the quality score after indel realignment. 23 The detection of single-nucleotide and indel polymorphisms was performed with the main algorithm of GATK on the basis of a Bayesian statistical model for the calculation of the probability of the genotype. 23 As confirmation of the accuracy of each call, the Phred-like quality score was associated with the variant results. Furthermore, each detected variant was annotated with information such as the genome position and functional effect with the ANNOVAR tool (version 2014, November 12). The filtering of variants after annotation was performed with an in-house-developed script in R software (https://www.r-project.org/). Because a dominant inheritance pattern was expected, homozygous variants were filtered out. Moreover, only variants predicted to cause a truncated protein product (frameshift or stop-gain mutations) were chosen. We also removed variants with an allelic frequency 1% in the 1000 Genomes Project (http:// www.1000genomes.org/), the Exome Variant Server (http://evs.gs.washington.edu/), and dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/). Variants were further considered on the basis of a gene's previously known biological function in BC.
Sanger Sequencing
Sanger sequencing of polymerase chain reaction products was performed on both strands with the BigDye Terminator v.3.1 cycle sequencing kit (Applied Biosystems, Foster City, Calif) in the ABI-Prism 3130XL genetic analyzer (Applied Biosystems). Polymerase chain reaction fragments and sequencing reactions were purified with the MultiScreen HTS vacuum manifold (Millipore, Billerica, Mass). The primer pairs used are available upon request.
Variants were named according to Human Genome Variation Society nomenclature (http://www.hgvs.org/) and were identified as new by reference to the Leiden Open Variation Database (version 3.0; http://databases. lovd.nl/), the Exome Aggregation Consortium browser (http://exac.broadinstitute.org/), and the Exome Variant Server.
Genotyping
Genotyping was conducted with a high-resolution melting analysis performed with the 7500 Fast real-time polymerase chain reaction system (Applied Biosystems). Primers were designed with the Primer3Plus platform and are available upon request. Samples from individuals carrying and not carrying the selected variant were used as positive and negative controls in each high-resolution melting experiment. Melting curves were analyzed with High Resolution Melting software (Applied Biosystems).
Fragments showing aberrant melting curves were analyzed with Sanger sequencing to determine the presence of genetic variations.
RESULTS
WES in a High-Risk, BRCA1/2 Mutation-Negative MBC Family WES was performed in a high-risk, BRCA1/2 mutationnegative MBC family selected from the ongoing Italian multicenter study of MBC. Three family members, including the proband, her paternal uncle, and her maternal aunt (Fig. 1A) , were analyzed. The mean coverage for all cases was >703. Results from the WES bioinformatics analysis are reported in Table 1 .
As a result of the variant filtering, 1 heterozygous truncating mutation, PALB2 c.419delA (p.Lys140Serf-sTer37), which was shared by the proband and her paternal uncle (both affected with BC), was considered as a causal pathogenic mutation. The mutation, located in exon 4 of PALB2, was successfully validated with Sanger sequencing (Table 2 and Fig. 1A) .
The proband was diagnosed with an estrogen receptor-positive, progesterone receptor-positive ductal carcinoma in situ at the age of 45 years; her father, a mutation obligate carrier, was diagnosed with a ductal carcinoma at the age of 66 years; and her paternal uncle was diagnosed with melanoma at the age of 65 years and with an estrogen receptor-positive, progesterone receptor-positive ductal carcinoma at the age of 76 years.
A nonsense, potentially deleterious variant in N-acetyltransferase 1 (NAT1; c.97C>T; p.Arg33Ter; rs56318881), a BC-related gene, was identified by WES in the proband's maternal aunt, who was diagnosed with BC at the age of 60 years. The mutation was confirmed by Sanger sequencing and was not detected in the proband.
Overall, NAT1 and PALB2 variants were observed on the maternal and paternal sides of the family, respectively. On the basis of the WES findings, we further performed a targeted sequencing of the complete coding region and intron/exon boundaries of PALB2 for 48 high-risk MBC patients negative for BRCA1/2 pathogenic mutations. As shown in Table 2 , a total of 9 PALB2 variants were identified by targeted sequencing. The PALB2 c.1984A>T (p.Lys662Ter) nonsense mutation was found in a man diagnosed with breast, lung, and prostate cancers at 60, 66, and 67 years of age, respectively (Fig. 1B) . This case had also an FH of BC on the maternal side of the family. Specifically, his mother and grandmother were both diagnosed with BC at 80 years of age. He also had a maternal aunt diagnosed with endometrial cancer at 80 years of age.
The mutation carrier presented with an estrogen receptor-negative, progesterone receptor-positive breast tumor. A sequencing analysis of tumor DNA obtained from his breast and lung tumors showed a loss of the wild-type allele in the breast tumor sample but not in the lung tumor sample (Fig. 1B) . We did not search for a different second-hit PALB2 mutation in the lung tumor sample.
Testing of PALB2 c.1984A>T in the mutation carrier's healthy offspring revealed that his son was a mutation carrier, whereas his daughter was wild-type (Fig. 1B) .
In addition to the PALB2 nonsense mutation, 4 PALB2 missense variants (p.Gln559Arg, p.Ile654Val, p.Glu672Gln, and p.Gly998Glu) and 1 synonymous variant (p.Thr11005), all previously reported, were identified in the analyzed series ( Table 2 ). The variants p.Gln559Arg, p.Ile654Val, and p.Glu672Gln were predicted to be neutral by in silico analysis, whereas the variant p.Gly998Glu was predicted to have a damaging effect. Furthermore, 3 noncoding variants-2 previously reported (g.5154G>A and g.9966A>C) and 1 novel (g.43066G>A)-were detected (Table 2 ). An in silico analysis predicted that these variants would not affect splicing.
NAT1 c.97C>T in MBC and FBC
High-resolution melting was performed to genotype the NAT1 c.97C>T nonsense variant in a case-control study including 331 BRCA1/2-negative MBC cases, 631 healthy male controls, 102 BRCA1/2-negative FBC cases, and 218 healthy female controls (Fig. 2) . The NAT1 c.97C>T variant was not found in any of the cases and controls analyzed.
DISCUSSION
In this study, we investigated the genetic causes of highrisk, BRCA1/2 mutation-negative MBC cases combining exome sequencing and targeted gene sequencing. We Original Article selected a high-risk, BRCA1/2 mutation-negative family with 2 first-degree MBC cases and 4 FBC cases to be analyzed by WES. This peculiar selection allowed the identification of a pathogenic PALB2 germ-line mutation associated with BC susceptibility in both sexes. We found that the proband, her father, and her paternal uncle, all affected with BC, were carriers of the PALB2 c.419delA truncating mutation; to our knowledge, this mutation has not been previously reported.
In a previous study, we performed PALB2 genetic screening in a population-based series of 97 MBC cases unselected for FH, and we did not identify any pathogenic mutation. 6 Here, we performed PALB2-targeted sequencing in a selected series of 48 high-risk, BRCA1/2 mutation-negative MBC patients from the ongoing Italian multicenter study of MBC. [13] [14] [15] In this series, we identified a PALB2 truncating mutation, c.1984A>T (p.Lys662Ter), in 1 MBC case, who presented with an FH of BC and a personal history of lung and prostate cancer. This mutation was previously reported in a French woman diagnosed with bilateral BC who presented with a personal history of colon cancer and an FH of prostate and pancreatic cancer. 30 We could show the loss of the wild-type allele in the breast tumor of our mutation carrier, and this further confirmed the pathogenic effect of the PALB2 c.1984A>T mutation.
In this study, we also identified 4 PALB2 missense variants (p.Gln559Arg, p.Ile654Val, p.Glu672Gln, and p.Gly998Glu) considered not pathogenic on the basis of either the previously reported polymorphic frequency in controls 6 or the neutral effect on protein function predicted by an in silico analysis. Nevertheless, it cannot be excluded that some of these variants may represent low-penetrance susceptibility polymorphisms, as recently suggested for the p.Gln559Arg variant. 29 If we consider the 2 MBC cases in the family analyzed by WES and the case identified in the series of 48 high-risk MBC cases, 3 cases from 2 high-risk families were carriers of pathogenic PALB2 mutations. Overall, 2 of 49 unrelated high-risk MBC cases (4%) were PALB2 mutation carriers.
To date, only a limited number of studies have investigated the presence of PALB2 mutations in MBC. [26] [27] [28] [31] [32] [33] [34] Previous studies, including a small number of high-risk MBC cases (up to 13 cases), showed a variable mutation frequency ranging from 1% to 16%. 26, 28, 31, 34 Our data, based on a series of high-risk MBC cases larger than those analyzed thus far, provide a more precise assessment of the contribution of PALB2 mutations in highrisk MBC cases. Notably, the frequency of PALB2 pathogenic mutations in high-risk MBC cases reported here was higher than that observed in high-risk FBC cases (ie, 4% vs 1%). 35 Our data show that MBC cases harboring PALB2 mutations were also affected by other tumors, including melanoma, prostate cancer, and lung cancer, and they had a FH of breast and other cancers, including stomach cancer. PALB2 mutations were frequently observed in pedigrees with cases of melanoma, pancreatic cancer, prostate cancer, lung cancer, and stomach cancer in addition to BC. [25] [26] [27] [28] [29] [30] [31] 34, 36 Overall, these observations suggest that PALB2-related families may resemble BRCA2-like families, in which MBC and several other cancers may be found in addition to FBC. However, further studies are needed to evaluate the risk conferred by PALB2 mutations in cancers other than BC. Because of the high BC risk recently associated with PALB2 mutations, 37 the identification of PALB2 mutation carriers in MBC is likely to be of significant clinical relevance. Recently introduced National Comprehensive Cancer Network practice guidelines suggest that female PALB2 mutation carriers should undergo enhanced breast screening. 38 Notably, in our study, we identified a young, healthy male PALB2 mutation carrier in a high-risk MBC family. We suggest that in the presence of PALB2 pathogenic mutations and a significant cancer FH, it is important to consider BC awareness and surveillance in male PALB2 mutation carriers, as recently indicated for male BRCA1/2 mutation carriers. 38 Thus, men with PALB2 mutations also may be candidates for personalized medical decisions according to the best available information about their cancer risk.
In this study, we also identified the rare nonsense variant NAT1 c.97C>T (rs56318881), also known as NAT1*19, in an FBC case. NAT1 encodes for an N-acetyltransferase involved in the metabolism of xenobiotics and carcinogens, and the NAT1 c.97C>T variant encodes for a truncated protein with impaired functionality. 39, 40 It has been shown that NAT1 variants may increase the risk of lung cancer and BC. [41] [42] [43] Notably, we found the NAT1 c.97C>T variant on the side of the pedigree in which 3 cases of BC and 2 cases of lung cancer were present. Unfortunately, DNA from family members affected with lung cancer was not available for testing. There is also evidence that NAT1 may have a possible role in MBC because NAT1 has been suggested to be a prognostic marker in MBC patients. 44 In this study, we investigated the potential role of NAT1 c.97C>T in genetic susceptibility to BC by genotyping a large case-control series. The variant was not found in any of the cases and controls analyzed, and this suggests that it may represent a rare, family-specific predisposition factor. However, given the low frequency of this variant in the population (minor allele frequency from the Exome Aggregation Consortium browser 5 0.00004), we cannot exclude a small effect of this variant on BC risk.
In conclusion, our results add strength to the accumulating evidence showing that PALB2 is involved in BC risk (particularly MBC) and suggest that MBC cases may be helpful in the identification of PALB2 families, as is the case for BRCA2 families. 45 PALB2 seems now to be ready for clinical translation, and PALB2 genetic testing should be considered for BRCA1/2 mutation-negative BC families with MBC and/or other cancers. Overall, results from this study highlight the importance of a good selection of high-risk BC families for genetic testing with the aim of improving the clinical management of MBC and FBC patients and their relatives.
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